Global Recombinant DNA Technology Market Size Study & Forecast, by Product (Medical, Non-medical), By Component Type (Expression System, Cloning Vector), By Application (Food & Agriculture, Health & Disease, Environment, Others), By End-use (Pharmaceutica

Global Recombinant DNA Technology Market Size Study & Forecast, by Product (Medical, Non-medical), By Component Type (Expression System, Cloning Vector), By Application (Food & Agriculture, Health & Disease, Environment, Others), By End-use (Pharmaceutical & Biotech Companies, Academic & Research Institutes, and Other), And Regional Analysis, 2023-2030

Global Recombinant DNA Technology Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Recombinant DNA Technology is a method primarily used to alter the phenotype of an organism (host) after introducing and integrating a genetically changed vector into the organism's genome. This procedure essentially entails the introduction of an unfamiliar piece of DNA structure into the genome that houses our gene of interest. Recombinant DNA technology is used to create newly developed recombinant genes. Recombinant DNA technology uses several techniques, equipment, and other particular procedures to produce artificial DNA in order to create the desired result. The rising government initiatives, rising emergence of recombinant insulin, surging demand for recombinant/ genetically modified products, coupled with the rising prevalence of chronic diseases are the most prominent factors that are propelling the market demand across the globe.

Additionally, the rapid expansion of the biopharmaceutical industry is playing a significant role in augmenting the global market expansion. Biopharmaceuticals are drugs that are produced using living organisms, and many of them are developed using recombinant DNA technology. According to Statista, in 2022, the biopharmaceuticals sector was estimated to account for USD 403.1 billion across the globe, which is projected to constantly rise and estimated to reach USD 974.5 billion by 2030. Also, the continuous progress of rDNA techniques has created novel opportunities for biopharmaceutical research by enabling the formation of a recombinant DNA molecule. The adoption of this technology is anticipated to be fueled by the presence of a strong biopharmaceuticals pipeline, particularly the pipeline for recombinant proteins. The expansion of this market is largely attributable to the development of recombinant products using rDNA techniques in conjunction with CRISPR/Cas9 nuclease, ZFN, and TALEN enabling simple & accurate genome editing with no constraints by organisms. Numerous review studies conducted by researchers have demonstrated the effectiveness of rDNA technology. Moreover, the technological advancements in genomics, as well as the rising R&D initiatives and strategic collaborations by market players presents various lucrative opportunities over the forecasting years. However, the risks associated with the use of genetically modified food and regulatory, scientific, and ethical challenges related with gene therapy are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Recombinant DNA Technology Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing number of biopharmaceutical manufacturing companies, along with growing research and development activities. For instance, in May 2022, PharmaJet announced that the National Institute on Ageing (NIA) branch of the National Institutes of Health (NIH) granted its partner, the Institute for Molecular Medicine (IMM), a USD 12 million award. The award funds the development of beta-amyloid vaccines based on recombinant proteins and DNA for the treatment and prevention of Alzheimer's disease (AD). Such studies are accelerating the market's expansion. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecasting years. The presence of low-cost manufacturing centers, rising awareness regarding the benefits of this technology, increasing patient pool, as well as rising investments by many government organizations are significantly propelling the market demand across the region.

Major market players included in this report are:
F. Hoffmann-La Roche Ltd (Genentech, Inc)
Profacgen
Amgen Inc
Novartis AG
GenScript
Pfizer Inc
Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Merck & Co., Inc.

Recent Developments in the Market:
In March 2022, VBI Vaccines Inc. unveiled the launch of PreHevbrio (Recombinant Hepatitis B Vaccine) for the treatment of individuals 18 years of age and older patients are at risk of contracting any of the identified subtypes of the hepatitis B virus (HBV).
In February 2022, the 3-antigen hepatitis B (HBV) vaccine manufactured by VBI Vaccines Inc. under the trade name PreHevbri received approval from the European Medicines Agency's Committee for Medicinal Products for Human Use. This vaccine is intended to protect adults from an infection caused by a particular subtype of the hepatitis B virus.

Global Recombinant DNA Technology Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Component Type, Application, End-use, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Medical
Non-medical

By Component Type:
Expression System
Cloning Vector

By Application:
Food & Agriculture
Health & Disease
Environment
Others

By End-use:
Pharmaceutical & Biotech Companies
Academic & Research Institutes
Other

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
F. Hoffmann-La Roche Ltd (Genentech, Inc)
Profacgen
Amgen Inc
Novartis AG
GenScript
Pfizer Inc
Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Merck & Co., Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.